| NCT ID | NCT05581745 |
| Status | Recruiting |
| Phase | — |
| Sponsor | University Health Network, Toronto |
| Condition | Lung Transplant |
| Study Type | INTERVENTIONAL |
| Enrollment | 10 participants |
| Start Date | 2022-07-14 |
| Primary Completion | 2027-12-31 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
You will actively receive the study intervention — which may be a drug, biologic, device, or procedure.
This trial targets 10 participants in total. It began in 2022-07-14 with a primary completion date of 2027-12-31.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
Blood group A2 to blood group O kidney and liver transplants have been shown to be safe and successful, especially in recipients with low pre-operative anti-A antibody titers and with the use of peri-operative antibody-depleting therapies. Since blood group O lung transplant candidates tend to have longer wait times and a higher waitlist mortality compared to other blood groups, we propose to conduct a prospective study of lung transplantation from blood group A2 donors to eligible blood group O recipients in an effort to increase the available donor pool. The aim of this study is to determine both the feasibility and safety of this specific type of ABO-incompatible lung transplant, and the impact of this practice on reducing transplant wait times among blood group O lung transplant candidates. This would represent the first prospective study of ABO-incompatible lung transplants worldwide.
Eligibility Criteria
Inclusion Criteria: * first lung transplant * blood group O recipient * low pre-operative anti-A antibody titers * consent to study participation Exclusion Criteria: * re-transplant * multiorgan transplant * positive virtual crossmatch at time of transplant
Contact & Investigator
Shaf Keshavjee, MD MSc FRCSC FACS
PRINCIPAL INVESTIGATOR
University Health Network, Toronto
Frequently Asked Questions
Who can join the NCT05581745 clinical trial?
This trial is open to participants of all sexes, aged 18 Years or older, studying Lung Transplant. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT05581745 currently recruiting?
Yes, NCT05581745 is actively recruiting participants. Contact the research team at sharaniyaa.balachandran@uhn.ca for enrollment information.
Where is the NCT05581745 trial being conducted?
This trial is being conducted at Toronto, Canada.
Who is sponsoring the NCT05581745 clinical trial?
NCT05581745 is sponsored by University Health Network, Toronto. The principal investigator is Shaf Keshavjee, MD MSc FRCSC FACS at University Health Network, Toronto. The trial plans to enroll 10 participants.